Hepatitis C related Press Releases
GlobeImmune's Hepatitis C Therapeutic Vaccine, GI-5005, Improves EVR Rates to 94 percent in Phase 2 Clinical Trial
GlobeImmune's Hepatitis C Therapeutic Vaccine, GI-5005, Improves EVR Rates to 94 percent in Phase 2 Clinical Trial LOUISVILLE, Colo.- April 23, 2009 - Twelve-week Phase 2 clinical trial data show
... Read more...Merck Announces Interim Phase IIa Study Results of MK-7009, an Investigational Oral Hepatitis C Virus Protease Inhibitor
Merck Announces Interim Phase IIa Study Results of MK-7009, an Investigational Oral Hepatitis C Virus Protease Inhibitor, in Patients with Chronic Hepatitis C
Phase IIb Trial will Further
... Read more...First evidence for DNA-based vaccination against chronic hepatitis C
First evidence for DNA-based vaccination against chronic hepatitis C Copenhagen, Denmark, Thursday 23 April: The first-proof-of-concept for a DNA-based therapeutic vaccination against chronic
... Read more...FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C New use for PEGINTRON(TM) and REBETOL(R) offers certain patients a second chance... Read more...
Math Patterns Show Who Will Respond to Hep C Treatment
Math Patterns Show Who Will Respond to Hep C Treatment Newswise - Genetic patterns are like the tea leaves in the bottom of a cup for predicting which patients are likely to respond to medical
... Read more...Public Statement on Viraferon (Interferon Alfa-2b) Withdrawal of the Marketing Authorisation in the European Union
Public Statement on Viraferon (Interferon Alfa-2b) Withdrawal of the Marketing Authorisation in the European Union LONDON, Nov. 20, 2008-On 9 March 2000, the European Commission granted a marketing
... Read more...Hepatitis C Therapeutic DNA Vaccine Delivered By Inovio Biomedical's Electroporation Technology Reduces Viral Load By Up To 99.7
Hepatitis C Therapeutic DNA Vaccine Delivered By Inovio Biomedical's Electroporation Technology Reduces Viral Load By Up To 99.7% Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the
... Read more...GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005, Doubles Viral Clearance and Increases RVR Rates in Phase 2 Clinical Trial
GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005, Doubles Viral Clearance and Increases RVR Rates in Phase 2 Clinical Trial Four-Week Data Comparing GI-5005 Plus Standard of Care vs. Standard
... Read more...Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 20
Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 Nearly 90 percent of patients achieve undetectable viral load in
... Read more...GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C PHILADELPHIA, October 29, 2008 /PRNewswire-FirstCall/ -- GlaxoSmithKline and
... Read more...Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
